Ogilvy Health’s new executive creative director brings big-name consumer experience to ‘less cynical’ health brands

Beth Snyder Bulik

Senior Editor

Ogilvy Health’s new executive creative director Erik Vervroegen has been around the agency world — literally. The Belgian native worked for both Grey and TBWA in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ogilvy Health’s new executive creative director brings big-name consumer experience to ‘less cynical’ health brands

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Ogilvy Health’s new ex­ec­u­tive cre­ative di­rec­tor brings big-name con­sumer ex­pe­ri­ence to ‘less cyn­i­cal’ health brands

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ogilvy Health’s new executive creative director brings big-name consumer experience to ‘less cynical’ health brands

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market